Introduction
The first widely used multi-agent chemotherapy program for advanced Hodgkin's lymphoma, MOPP (mechlorethamine, vincristine, procarbazine and prednisone), produced a response rate of 80% and long-term disease-free survival of ∼50% [1, 2] , but burdened the patient with two major long-term health risks. Myeloid leukemia or myelodysplastic syndrome develops in ∼3% to 5% of patients treated with MOPP, and gonadal toxicity is encountered frequently, leading to infertility and premature menopause in about one-half of women and oligospermic infertility in most men.
ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) was developed by the Milan group in 1973 [3] . It has partial non-cross-resistance with MOPP and can cure ∼20% of patients not cured with that regimen [4] . ABVD also has less pronounced long-term toxicity, causing neither sterility nor premature menopause and being less leukemogenic [5, 6] .
Hybrid or alternating combinations of MOPP and ABVD were widely tested in the 1980s and were shown to be superior to MOPP by virtue of curing ∼10-15% more patients [7] . More recently, however, ABVD by itself was shown to produce results as good as the hybrid regimens, and to be less toxic [8, 9] . In a landmark randomized trial the Cancer and Acute Leukemia Group B (CALGB) compared MOPP, ABVD and alternating MOPP/ABVD in advanced-stage Hodgkin's lymphoma (stages IIIA, IIIB, IVA, IVB) [8] ( Table 1) .
There was no statistically significant difference in overall survival across the three arms; however, that endpoint is obscured by secondary treatment such as high-dose chemotherapy with autologous hematopoietic stem-cell transplantation (autoSCT). The important observation, however, was that ABVD and MOPP/ABVD produced equivalent progressionfree survival and both were significantly better than MOPP. These results were confirmed in a large intergroup study with participation from the CALGB, the Eastern Cooperative Oncology Group (ECOG), the National Cancer Institute of Canada Clinical Trials Group (NCIC) and the Southwest Oncology Group (SWOG), in which the MOPP/ABV hybrid regimen was tested against ABVD [9] . This trial enrolled 856 patients and found no differences in complete response (CR), freedom from treatment failure or overall survival between the two regimens.
Because the ABVD regimen works as well as the seven and eight drug hybrid combinations, does not cause leukemia, infertility or premature menopause, and induces less cumulative myelotoxicity, by the end of the 1990s it had become recognized as the best standard chemotherapy available for Hodgkin's lymphoma. The challenge facing clinical investigators at that time was to develop new regimens capable of curing more than the approximately 65% of patients with advanced-stage Hodgkin's lymphoma ordinarily cured with ABVD without increasing the burden of major long-term toxicity so much as to offset the gains in cure rates. However, how to proceed and how to tailor intensity of treatment to likelihood of cure and tolerance for toxicity awaited improved methods of differentiating subgroups of patients with different prognoses.
Recently, the whole approach to advanced Hodgkin's lymphoma was placed on a more rational footing by the International Prognostic Factors Project on Advanced Hodgkin's Disease (IPFP), which developed a robust prognostic model that identifies patients with differing risk of primary treatment failure. Seven independent predictors of decreased likelihood of freedom from progression and survival after ABVD chemotherapy can be used for this purpose (Table 2 ). Subgroups of patients can be identified with varying likelihood of freedom from progression on the basis of the number of these factors present at diagnosis, as shown in Table 3 . For the 80% of patients with up to three of these factors, the likelihood of 5-year progression-free survival is 70%. For the 20% who have four or more of these factors, the 5-year progression free survival falls to <50%. Knowledge of this prognostic factor score is helpful in guiding treatment choice and is essential for interpreting the results of clinical trials.
New regimens
Two major new regimens for the treatment of patients with advanced Hodgkin's lymphoma were described during the 1990s. In the Stanford V regimen the chemotherapy drugs are administered weekly for 12 weeks, followed by irradiation with 36 Gy to sites of initial tumor bulk (≥5 cm) [10, 11] . The mature results of the phase II study of 142 patients treated with this regimen showed, with a median follow-up of 5.4 years, an actuarial 5-year survival of 96% and freedom from progression of 89% [12] . Fertility was preserved and no leukemias have been observed.
The German Hodgkin Lymphoma Study Group has developed a dose-escalated and accelerated combined modality program, BEACOPP + RT (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone followed by involved region radiation for sites of initial or residual bulk) [13] . A randomized trial has been performed comparing COPP/ABVD + RT with standard dose BEACOPP + RT and escalated dose BEACOPP + RT. Irradiation was given to ∼70% of patients on all three arms. A fifth interim analysis with 1180 evaluable patients and a median follow-up of 36 months showed the outcomes noted in Table 4 . Although BEACOPP in escalated dose showed a higher but manageable rate of hematological toxicity, substantial toxicity was encountered: 3% treatment-induced mortality, 100% infertility in men, 100% infertility plus premature menopause in most women over the age of 25 years.
North American trials
The last large clinical trial for advanced Hodgkin's lymphoma completed in North America was the intergroup comparison of ABVD with MOPP/ABV hybrid [9] . It established ABVD as the standard treatment for everyday clinical use and the standard arm for future clinical trials. Three possible strategies have been examined in sufficient detail to justify comparison with ABVD: Stanford V plus radiation, BEACOPP plus radiation, or high-dose chemotherapy with autoSCT. Each of these approaches holds the promise of curing more patients and therefore needs to be tested against the current standard. The North American cooperative groups have structured their current round of clinical trials for advanced Hodgkin's lymphoma around testing these promising new ideas.
Current and future trials of treatment for advanced Hodgkin's lymphoma must take into consideration the impact of the IPFP score. The German Hodgkin Study Group trial of COPP/ABVD, standard or escalated BEACOPP + RT showed that much of the benefit of the aggressive experimental approaches was visited on a minority of patients with the highest score (Table 4) . Indeed, the approach to clinical trials in North America is structured around consideration of the IPFP score (Table 5 ). For the approximately 60% of patients with an IPFP score of 0-2, who therefore have a predicted 5-year progression-free survival probability of ∼75% with ABVD chemotherapy, the focus will be on trying to increase the likelihood of cure without incurring exaggerated toxicity. For the 40% of patients with a score of ≥3, who have a 5-year progression-free survival probability of only 55% with ABVD, the increased toxicity that may come with more intensive treatment appears justified if it is accompanied by improved disease control.
For the patients with advanced Hodgkin's lymphoma with only 0-2 IPFP factors, ECOG has been joined by SWOG, NCIC and CALGB in conducting trial E2496, which is comparing ABVD plus radiation, reserved for patients with initially very bulky disease (>10 cm), with Stanford V plus radiation for patients with initially moderately bulky disease (>5 cm). The hope is to match or exceed the 75% progressionfree survival expected from ABVD with no more, or even less, long-term toxicity. All four North American cooperative groups have committed their resources to completing this important trial. For patients with poorer prognosis advanced-stage Hodgkin's lymphoma, those with an IPFP score of ≥3, the initial plan of SWOG, ECOG and CALGB was to examine the potential to improve outcome by adding high-dose chemotherapy and autoSCT. They opened a trial of ABVD for eight cycles versus a shorter course of ABVD followed by highdose chemotherapy and autoSCT. Unfortunately this trial has been closed without adequate accrual for interpretation. Currently, these same groups are considering what direction to adopt next. One possibility would be to expand enrollment in E2496 (ABVD versus Stanford V) to all prognostic groups. A firm decision has not yet been made.
The NCIC has decided to adopt a different approach to the patients with an IPFP score of ≥3. This group will join the European Organization for Research and Treatment of Cancer (EORTC) to test ABVD versus BEACOPP without radiation. This trial will complement the current German Hodgkin Study Group four-arm HD 12 trial, which is also testing BEACOPP without radiation as one experimental approach. These two trials, the EORTC/NCIC trial and the German HD 12 trials, will jointly address two major questions. First, the role of radiation in the BEACOPP program will be definitively examined, and secondly, the efficacy and toxicity of BEACOPP without radiation relative to the North American standard of ABVD will be determined.
Conclusions
The majority of adult patients with advanced-stage Hodgkin's lymphoma can be cured with treatments that have been identified and refined in extensive clinical trials over the last 30 years. Continued clinical investigation of this type and caliber is the only way that further progress will be made. Building on their success in combining the efforts of investigators across several large cooperative groups, the North American cooperative oncology groups are continuing to seek the optimal treatment approach. Having confirmed that ABVD chemotherapy is the current standard of treatment, these groups are now attempting to improve on it by exploring the potential of new regimens such as Stanford V and BEACOPP. These efforts, complemented and challenged by the findings from equally important trials in Europe and elsewhere, will continue the steady progress that has characterized the management of this often, but not always, cured malignancy. 
